Virometix Ag

Unversität Zürich

Universitaet Zuerich

Swiss Tropical and Public Health Institute

University of Basel

Universität Zürich, Prorektorat Forschung

Arin Ghasparian

John Anthony Robinson

Kerstin Möhle

Armando Zuniga

Aniebrys Marrero Nodarse

Kerstin Moehle

Gerd Pluschke

Francesca Boato

Oliver Rassek

Richard M Thomas

Anabelle Freund

Maja Jud

Marco Tamborini

Nina Geib

Annabelle Freund

John A Robinson

LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES

The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.

Cyclic peptides for protection against respiratory syncytial virus

The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline. Such synthetic virus-like particles carrying proline-rich antigens derived from pneumococcal proteins are useful as vaccines against infectious diseases caused by Gram-positive bacteria such as

[object Object]

The invention relates to lipopeptide building blocks consisting of a peptide chain comprising a coiled-coil domain, linked covalently to a lipid moiety comprising long alkyl or alkenyl chains, and optionally linked to an antigen; and to helical lipopeptide bundles and synthetic virus-like particles formed by aggregation. The nanometer size and shape of these bundles and particles, their stability under aqueous physiological conditions, their chemical composition, the possibility to incorporate B- and T-cell epitopes, and their production by chemical synthesis, make them highly suitable as vaccine delivery vehicles.

Coiled-coil lipopeptide helical bundles and synthetic virus-like particles

Growing community of inventors

Zurich, Switzerland

Arin Ghasparian